Italia markets open in 7 hours 38 minutes

Teva Pharmaceutical Industries Limited (TEVJF)

Other OTC - Other OTC Prezzo differito. Valuta in USD.
Aggiungi a watchlist
9,610,00 (0,00%)
Alla chiusura: 09:46AM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente9,61
DenaroN/D x N/D
LetteraN/D x N/D
Min-Max giorno9,61 - 9,61
Intervallo di 52 settimane7,00 - 12,73
Media Volume72
Beta (5 anni mensile)1,19
Rapporto PE (ttm)N/D
EPS (ttm)-0,56
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendo28 nov 2017
Stima target 1AN/D
  • GlobeNewswire

    Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

    The U.S. Food and Drug Administration’s (FDA) regulatory review is anticipated to be completed in the second half of 2023Stelara® (ustekinumab) is prescribed to treat a variety of inflammatory conditions REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industrie

  • GlobeNewswire

    Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®

    U.S. Food and Drug Administration (FDA) has confirmed that the goal date for an approval decision on Alvotech’s license application for AVT02 is April 13, 2023 FDA has completed review of Alvotech’s application of AVT02 as an interchangeable to high-concentration of Humira® and confirmed that the data provided are sufficient to support a determination of interchangeability; approval requires satisfactory outcome of upcoming facility reinspectionAlvotech is anticipating a facility reinspection by

  • GlobeNewswire

    Certara Appoints Rosemary Crane as New Independent Board Member

    PRINCETON, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Rosemary Crane to its Board of Directors, effective July 21, 2022. Her appointment brings the company’s board of directors to eleven members. “We are excited to welcome an accomplished business leader with a proven track record of success join Certara’s Board,” said William F. Feehery, PhD, CEO of Certara. “Rose’s experience in executive leadership